The Impact Of Artificial Intelligence And Machine Learning On Drug Development

Abstract

Aim: To analyze how artificial intelligence (AI) and machine learning (ML) are revolutionizing drug discovery and development by addressing inefficiencies in the pharmaceutical industry.
Objective: To explore the impact of AI and ML on improving efficiency, precision, and decision-making across various stages of the drug development pipeline.
Purpose: To highlight the transformative role of AI and ML in reducing timeframes, costs, and attrition rates, while enhancing patient outcomes in drug development.
Discussion: The integration of AI and ML into drug discovery leverages large datasets such as proteomic, metabolomic, and genomic information to identify novel therapeutic options and pharmacological targets that traditional methods might miss. Advances like AlphaFold have revolutionized protein structure prediction, while AI-driven virtual screening expedites chemical library assessment, minimizing time and resource expenditure. In clinical trials, AI optimizes patient recruitment by analyzing electronic health records (EHRs), ensuring diverse trial populations and enhancing trial reliability. Adaptive trial designs, supported by real-time data analysis, enhance patient safety and treatment efficacy. However, challenges such as data quality, ethical considerations, and evolving regulatory frameworks need to be addressed.
Conclusion: AI and ML are transforming drug development, but their full potential can only be realized through collaboration between the pharmaceutical and technology sectors to overcome existing barriers and improve patient outcomes.